Presenter: Emma Morris Presenter's Affiliation: UK Collaborative Group, United Kingdom Type of Session: Scientific
Campath is an antibody that targets CD 52 which is a T cell marker.
Campath has been studied in induction therapies for myeloablative transplants.
This study looked at Campath as additional therapy for reduced intensity allogeneic stem cell therapy for NHL.
Materials and Methods
93 total pts were enrolled with a predominance of men
Median pt age was 43 years
46 pts had low grade or indolent lymphoma and 47 had intermediate or high grade lymphoma.
The median number of previous therapies for all pts was 3.
Campath was given from 9 days prior to transplant to day minus 4. A conditioning regimen of Fludarabine and Melphalan was used.
Cyclosporin was used as GVH prophylaxis.
91 of the 93 pts had full engraftment. One graft rejection was seen and one death occured prior to engraftment.
75% of the pts experienced no GVHD. 11% had grade I GVHD, and only 4% had grade III-IV GVHD.
Treatment related mortality at day 100 was 13% and at one year 17%.
After 26 months of follow up overall survival was 64% for all.
Overall survival for low grade lymphoma was 80% whereas for high grade disease survival was 33%.
Campath use for in vivo T cell depletion reduces the incidence and severity of GVHD while getting 80% overall survival rates for low grade indolent lymphoma.
These data imply that bone marrow T cell depletion can be adequately and efficiently done with Campath induction therapy. This may have cost and time saving implications for T cell depleted bone marrows. Further studies of this agent are indicated.
Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.
Oct 13, 2011 - More than one third of the long-term survivors of non-Hodgkin's lymphoma experience persistence or worsening of the symptoms of post-traumatic stress disorder, according to a study published online Oct. 10 in the Journal of Clinical Oncology.